Investment
Features
FeesSafety
Academy
More
Pluang+

Regeneron rebounds with strong drug pipeline, raising valuation to $1,230/share from $750/share.

Analyst Insights
27 Apr 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Regeneron has recovered from previous regulatory and clinical challenges, driven by key drugs like Dupixent, Lynozyfic, and cemdisiran. The company’s pipeline focuses on obesity, complement-mediated diseases, myeloma, solid tumors, and anticoagulation, positioning it for medium-term growth. Analysts have raised Regeneron's valuation to $1,230 per share, up from around $750, supported by a 15% free cash flow growth outlook and strong execution of its pipeline. Investors see significant upside as the market currently undervalues Regeneron's innovation potential despite competitive and regulatory pressures.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App